-
What attracts BioNTech to expand its antibody and cell therapy layout with over $790 million in cooperation?
Time of Update: 2022-01-24
Summary Crescendo's Humabody VH platform includes not only heavy chain-only novel antibody molecules, but also the development of novel T cell engagers, which coincides with the novel antigen T cell therapy in BioNTech's R&D pipeline .
-
JAMA sub-issue: Top medical institutions confirm that drinking more coffee reduces colorectal cancer deaths and prolongs survival
Time of Update: 2022-01-24
Written | Edited by Wang Cong | Typesetting by Wang Duoyu | Shui Chengwen On September 17, 2020, Mayo Medical Center, Dana-Farber Cancer Institute and other top international medical research institu
-
NiKang Therapeutics: The first HIF-2α inhibitor enters the clinic JPM 2022
Time of Update: 2022-01-24
Gao Zhenhai, co-founder, president and CEO of NiKang Therapeutics (hereinafter referred to as NKT), gave a keynote speech at the 40th JPMorgan Chase Healthcare Annual Conference, introducing the basic situation of the company to investors .
-
Change the tumor microenvironment!
Time of Update: 2022-01-24
January 13, 2022 / eMedClub News/--January 11, 2022, Phio Pharmaceuticals, a proprietary self-delivering RNAi (INTASYL™) therapeutic platform, a biotechnology company developing next-generation immuno-oncology therapeutics, Recently, it was announced that PH-762 was granted Clinical Trial Authorization (CTA) by the French National Agency for the Safety of Medicines and Health Products .
-
Kewan: Turning Cold Tumors into "Fire"｜JPM 2022
Time of Update: 2022-01-24
Ji Xiaohui, the co-founder and CEO of Kewang Medicine, as a speaker, introduced Kewang's distinctive positioning: through the development of a new generation, differentiation, and curative effect "Global new" or "best-in-class" tumor immunotherapy, turning "cold tumors" into "hot tumors", for those about 70% who do not respond to PD-1/PD-L1 inhibitors, or develop resistance of cancer patients worldwide with new treatment strategies .
-
Nature sub-journal: Step on the accelerator for the immune system, MIT develops IL-12+ alum therapy, which effectively kills tumors and has fewer side effects
Time of Update: 2022-01-24
The study developed a new method to prime the immune system by combining the cytokine IL-12 with aluminum hydroxide (alum) and delivering it to tumors, activating tumor immunity while avoiding the use of immune-stimulating drugs throughout the body possible toxic reactions .
-
JPM points to KRAS and p53 mutations driving cancer, new TCR cell therapy debuts
Time of Update: 2022-01-24
▲The company has discovered selective TCRs for KRAS G12V and KRAS G12D (Image source: Affini-T's official website) Affini-T's cell therapy design not only expresses TCR targeting oncogenic mutation targets in CD4-positive and CD8-positive T cells TCR, but also expresses a CD8 co-receptor .
-
Professor Liu Yinhua: Summary and Hope, Review and Future Prospects of Breast Surgery and Neoadjuvant Therapy
Time of Update: 2022-01-24
Currently, the Center for Breast Diseases has undertaken two multicenter studies from the Breast Surgery Group of the Chinese Medical Association, among which the CSBrS-015 study evaluated HER-2 positive early breast cancer receiving trastuzumab combined with chemotherapy and trastuzumab + Pathological complete response (pCR) rate and tolerability of neoadjuvant therapy with Pertuzumab combined with chemotherapy regimen.
-
What about EGFR-TKI resistance?
Time of Update: 2022-01-24
After gefitinib treatment, the tumor progressed to stage IV and developed secondary resistance to EGFR, and the gene test was EGFR 19del with MET amplification .
-
Express Improves the Efficacy of Immune Checkpoint Inhibitors, Innovative Cancer Vaccine Enters Phase 2/3 Clinical Trials
Time of Update: 2022-01-24
"Reference: [1] Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC).
-
Express uses red blood cells to extensively stimulate the immune system, and innovative anti-cancer therapy enters the clinic
Time of Update: 2022-01-24
▎WuXi AppTec Content Team Editor On January 13, 2022, Rubius Therapeutics announced that its Phase 1/2 clinical trial of RTX-224, a red blood cell therapy designed to broadly stimulate the immune system, has completed the first patient dosing for For the treatment of certain patients with relapsed/refractory or locally advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelial (bladder) cancer, and triple-negative breast cancer .
-
In 28 years, the cancer death rate dropped by 32%!
Time of Update: 2022-01-24
Lung cancer mortality rates have declined dramatically in recent years due to declining smoking numbers, early detection, and advances in treatment .
Pancreatic cancer is the third leading cause of cancer death for both men and women in the United States, between 2000 and 2019: The mortality rate for men increased slowly, from 12.
-
A new carrier of tumor therapy drugs!
Time of Update: 2022-01-24
On January 12, 2022, Zhang Xu's team from Jiangsu University School of Medicine published a paper on "Engineered neutrophil-derived exosome-like vesicles for targeted cancer therapy" in Science Advances, a sub-journal of Science .
-
Hepatology China Pharmaceutical University Yang Yong and other teams discover potential new therapeutic targets for hepatocellular carcinoma
Time of Update: 2022-01-24
Therapeutic blockade of the iNature programmed cell death protein-1 (PD-1) immune checkpoint pathway leads to significant reactivation of T cell-mediated antitumor immunity and is a promising clinica
-
The results of the selection of the top ten research progress in China's hematology in 2021 were announced at the 2nd China Hematology Development Conference
Time of Update: 2022-01-24
This study revealed a new mechanism for the maintenance of hematopoietic stem cell function, and laid a theoretical foundation for in-depth exploration of the epitranscriptional regulation mechanism of blood ecology under physiological and pathological conditions .
-
[Nature sub-issue] Too cunning, "anti-cancer magic drug" PARP inhibitor can also allow cancer cells to escape! Research reveals the secret of how cancer cells resist targeted therapy
Time of Update: 2022-01-24
Excitingly, this study shows that drugs currently used to treat alcohol addiction can be combined with PARP inhibitors to make the treatment of breast cancer caused by a mutated BRCA gene more effective .
-
Highlights of CStone's sugalimab in the treatment of stage III/IV NSCLC concurrently published in "The Lancet-Oncology"
Time of Update: 2022-01-24
Yimaike's recent hot reports ★CStone Pharmaceuticals and Hengrui Medicine reached a strategic cooperation of 1. 3 billion yuan to accelerate the development and commercialization of tumor immune skel
-
Eli Lilly's Abecili Tablets Adds Indications, Opening a New Era of Early Breast Cancer Treatment
Time of Update: 2022-01-24
That is, abeccil tablets combined with endocrine therapy (tamoxifen or aromatase inhibitor) as adjuvant therapy are suitable for hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, lymph node positive, high Adult patients with early-stage breast cancer at risk of recurrence and Ki-67 ≥20% .
-
Wu Hong's group reveals a new mechanism for transforming "cold" tumors into "hot" tumors to promote prostate cancer immunotherapy
Time of Update: 2022-01-24
This study found that a novel PI3K inhibitor, BAY1082439, could improve the response of cancer cells to immune checkpoint blockade therapy by modulating the immunosuppressive pathway and tumor immune microenvironment in PTEN-deficient prostate cancer, providing clinical evidence for prostate cancer patients benefiting from immunotherapy.
-
Data analysis of nearly 3 million colonoscopy examinations: the starting age of colorectal cancer screening should be advanced to 45 years old
Time of Update: 2022-01-24
Therefore, larger surveys of colorectal cancer incidence in people between the ages of 45 and 49 years or in the years prior to the new recommended screening age are needed to identify additional risk factors .
